Jennifer Kayden Lee sold $4.4M of Rhythm Pharmaceuticals (RYTM)

Executed Nov 11 2024, disclosed Nov 13 2024, 2 days later.

Value, as filed

$4.4M

66,661 sh across 3 lots

Executed

Nov 11 2024

the trade date, as filed

Disclosed

Nov 13 2024

2 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

JL Jennifer Kayden Lee EVP, Head of North America profile →

Jennifer Kayden Lee (EVP, Head of North America) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in Rhythm Pharmaceuticals, Inc. (RYTM). The largest single filing was $8.9M of RYTM (75,834 sh × $117.38, as filed), executed Aug 13.

The name

RYTM Rhythm Pharmaceuticals, Inc. RYTM · Healthcare · 47 filings in 24 months ticker →

Healthcare · Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United State…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Jennifer Kayden Lee in RYTM

RYTMSALE Rhythm Pharmaceuticals, Inc. $8.9M
75,834 sh × $117.38
Exec Aug 13
Filed Aug 14 · 7:04 PM ET RYTMSALE Rhythm Pharmaceuticals, Inc. $116K
2,035 sh × $57.22
Exec Feb 19 2025
Filed Feb 19 2025 · 5:30 PM ET RYTMSALE Rhythm Pharmaceuticals, Inc. $247K
4,189 sh across 2 lots
Exec Feb 10 2025
Filed Feb 11 2025 · 5:30 PM ET RYTMSALE Rhythm Pharmaceuticals, Inc. $104K
1,733 sh × $60.08
Exec Feb 5 2025
Filed Feb 7 2025 · 5:30 PM ET